The Supreme Court’s temporary stay expired at 5 p.m. ET on May 14, putting the Fifth Circuit’s nationwide mifepristone restrictions back into effect.
That immediately suspends the FDA’s 2023 telehealth and mail-order rules, rolling access to the abortion pill back to in-person dispensing nationwide.
Providers now face a patchwork response: some may shift to misoprostol-only care, while shield-law states and telemedicine networks weigh how far they can keep serving patients across state lines.
Julie Kay of Reproductive Futures said enforcement pressure is likely to fall more on manufacturers and distributors than clinicians, though legal uncertainty itself can chill care and hit under-resourced patients hardest.
The rollback lands in a post-Dobbs system where telemedicine abortion, advance provision and state shield laws have expanded, setting up further legal and political fights over FDA authority and abortion access.
With the FDA's authority challenged, what does this mean for the future of approved medicines in America?
With mifepristone restricted, will its lesser-known alternative become the new standard for at-home abortion care?
As a federal court order clashes with state laws, can 'shield' states truly protect their medical providers?
Supreme Court Extends Telehealth Abortion Pill Access: The High-Stakes Legal Battle Over Mifepristone in 2026
Overview
On May 14, 2026, the Supreme Court issued a key decision that temporarily keeps telehealth and mail access to the abortion pill mifepristone available, even as Justice Alito's administrative stay expired. This move prevents an immediate rollback of access that many feared, while the legal battle in Louisiana v. FDA continues. Louisiana is challenging the FDA’s rules on mifepristone, aiming to restrict its use, but the Supreme Court’s action means patients and providers can still use telehealth and mail to get the medication for now. The situation remains uncertain as the broader legal fight unfolds.